A recent analysis comparing people with systemic lupus erythematosus (SLE) receiving belimumab (Benlysta®) with those receiving standard of care treatment (SoC) showed belimumab, plus SoC treatment results in lower rates of organ damage accrual compared with SoC treatment alone. The findings are consistent with previous clinical trials which show better outcomes in people who receive belimumab and SoC therapy compared to placebo and SoC treatment alone. Continue to follow the Lupus Foundation of America for updates on belimumab.

Read the analysis